Andrew Sinclair, Director at SOLENO THERAPEUTICS INC (SLNO), bought 2,300,000 shares at $1.20 ($2.8M) on 2019-10-25, disclosed to the SEC on 2019-10-29.
Open-market purchase of $2.8M SLNO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| SLNO | BUY | 2020-07-06 | $11.0M | — | Filing → |
| SLNO | BUY | 2018-12-27 | $14.9M | — | Filing → |